NBIX:NASDAQ
Neurocrine Biosciences, Inc
141,37 USD
arrow_downward
−0,75%(−1,07) 1D
141,37 USD
0,00% (0,00)
bedtimeNakon radnog vremena
Zatvoreno: 12. lis, 16:00:00 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za NBIX...
Otvori
142,37 USD
Najviša
143,62 USD
Najniža
140,89 USD
Trž. kap.
14,37 mlr.
Prosj. kol.
1,29 mil.
Količina
0,00
P/E omjer
20,72
52-tjed. najviša
186,12 USD
52-tjed. najniža
122,14 USD
EPS
6,82 USD
Beta
0,40
Dionice u optjecaju
101,65 mil.
Broj djelatnika
2 tis.
Otvori
142,37 USD
Najviša
143,62 USD
Najniža
140,89 USD
Trž. kap.
14,37 mlr.
Prosj. kol.
1,29 mil.
Količina
0,00
P/E omjer
20,72
52-tjed. najviša
186,12 USD
52-tjed. najniža
122,14 USD
EPS
6,82 USD
Beta
0,40
Dionice u optjecaju
101,65 mil.
Broj djelatnika
2 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Stock Titan
·
prije 10 sati
Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call.
Profil
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Neurocrine Biosciences, Inc – informacije
Glavni izvršni direktorKevin C. Gorman
Zaposlenici2,5 tis.
Osnovano1992
SjedišteSan Diego, Kalifornija, Sjedinjene Američke Države
Sektor-
Web-lokacijaneurocrine.com